The potential role of octreotide in the treatment of diabetic retinopathy

Maria B. Grant, Sergio Caballero

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Proliferative diabetic retinopathy is the main cause of vision loss in young and middle-aged adults. There is no accepted pharmaceutical therapy for this disease, although analogs of the naturally occurring growth hormone inhibitor, somatostatin, have been considered leading candidates for developing such therapies. This review examines the history of somatostatin analogs, especially octreotide, in the treatment of ocular complications of diabetes mellitus. The historical observations that indicated a role for somatostatin in retinopathy are discussed from an endocrinology perspective. The molecular mechanisms by which somatostatin may exert its antiangiogenic effects, both indirect (through antagonism of the growth hormone axis) and direct (through direct antiproliferative and apoptotic effects on endothelial cells mediated by specific receptor subtypes) are described. Animal models that were used to demonstrate an anti-angiogenic effect of octreotide are detailed, as are the results of numerous clinical trials that used octreotide and other somatostatin analogs to treat diabetic retinopathy. The mixed results of these clinical results are examined along with possible explanations as to why these analogs both have and have not shown efficacy in limited clinical settings. Even with these mixed results, somatostatin analogs remain the only therapeutic alternative to patients with proliferative diabetic retinopathy who have failed to respond to panretinal photocoagulation.

Original languageEnglish (US)
Pages (from-to)199-203
Number of pages5
JournalTreatments in Endocrinology
Volume4
Issue number4
DOIs
StatePublished - 2005
Externally publishedYes

Fingerprint

Octreotide
Diabetic Retinopathy
Somatostatin
Growth Hormone
Therapeutics
Growth Inhibitors
Light Coagulation
Endocrinology
Diabetes Complications
Endothelial Cells
Animal Models
History
Clinical Trials
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Endocrinology

Cite this

The potential role of octreotide in the treatment of diabetic retinopathy. / Grant, Maria B.; Caballero, Sergio.

In: Treatments in Endocrinology, Vol. 4, No. 4, 2005, p. 199-203.

Research output: Contribution to journalArticle

Grant, Maria B. ; Caballero, Sergio. / The potential role of octreotide in the treatment of diabetic retinopathy. In: Treatments in Endocrinology. 2005 ; Vol. 4, No. 4. pp. 199-203.
@article{03d95d103b7145668e927d4c22242806,
title = "The potential role of octreotide in the treatment of diabetic retinopathy",
abstract = "Proliferative diabetic retinopathy is the main cause of vision loss in young and middle-aged adults. There is no accepted pharmaceutical therapy for this disease, although analogs of the naturally occurring growth hormone inhibitor, somatostatin, have been considered leading candidates for developing such therapies. This review examines the history of somatostatin analogs, especially octreotide, in the treatment of ocular complications of diabetes mellitus. The historical observations that indicated a role for somatostatin in retinopathy are discussed from an endocrinology perspective. The molecular mechanisms by which somatostatin may exert its antiangiogenic effects, both indirect (through antagonism of the growth hormone axis) and direct (through direct antiproliferative and apoptotic effects on endothelial cells mediated by specific receptor subtypes) are described. Animal models that were used to demonstrate an anti-angiogenic effect of octreotide are detailed, as are the results of numerous clinical trials that used octreotide and other somatostatin analogs to treat diabetic retinopathy. The mixed results of these clinical results are examined along with possible explanations as to why these analogs both have and have not shown efficacy in limited clinical settings. Even with these mixed results, somatostatin analogs remain the only therapeutic alternative to patients with proliferative diabetic retinopathy who have failed to respond to panretinal photocoagulation.",
author = "Grant, {Maria B.} and Sergio Caballero",
year = "2005",
doi = "10.2165/00024677-200504040-00001",
language = "English (US)",
volume = "4",
pages = "199--203",
journal = "Treatments in Endocrinology",
issn = "1175-6349",
publisher = "Adis International Ltd",
number = "4",

}

TY - JOUR

T1 - The potential role of octreotide in the treatment of diabetic retinopathy

AU - Grant, Maria B.

AU - Caballero, Sergio

PY - 2005

Y1 - 2005

N2 - Proliferative diabetic retinopathy is the main cause of vision loss in young and middle-aged adults. There is no accepted pharmaceutical therapy for this disease, although analogs of the naturally occurring growth hormone inhibitor, somatostatin, have been considered leading candidates for developing such therapies. This review examines the history of somatostatin analogs, especially octreotide, in the treatment of ocular complications of diabetes mellitus. The historical observations that indicated a role for somatostatin in retinopathy are discussed from an endocrinology perspective. The molecular mechanisms by which somatostatin may exert its antiangiogenic effects, both indirect (through antagonism of the growth hormone axis) and direct (through direct antiproliferative and apoptotic effects on endothelial cells mediated by specific receptor subtypes) are described. Animal models that were used to demonstrate an anti-angiogenic effect of octreotide are detailed, as are the results of numerous clinical trials that used octreotide and other somatostatin analogs to treat diabetic retinopathy. The mixed results of these clinical results are examined along with possible explanations as to why these analogs both have and have not shown efficacy in limited clinical settings. Even with these mixed results, somatostatin analogs remain the only therapeutic alternative to patients with proliferative diabetic retinopathy who have failed to respond to panretinal photocoagulation.

AB - Proliferative diabetic retinopathy is the main cause of vision loss in young and middle-aged adults. There is no accepted pharmaceutical therapy for this disease, although analogs of the naturally occurring growth hormone inhibitor, somatostatin, have been considered leading candidates for developing such therapies. This review examines the history of somatostatin analogs, especially octreotide, in the treatment of ocular complications of diabetes mellitus. The historical observations that indicated a role for somatostatin in retinopathy are discussed from an endocrinology perspective. The molecular mechanisms by which somatostatin may exert its antiangiogenic effects, both indirect (through antagonism of the growth hormone axis) and direct (through direct antiproliferative and apoptotic effects on endothelial cells mediated by specific receptor subtypes) are described. Animal models that were used to demonstrate an anti-angiogenic effect of octreotide are detailed, as are the results of numerous clinical trials that used octreotide and other somatostatin analogs to treat diabetic retinopathy. The mixed results of these clinical results are examined along with possible explanations as to why these analogs both have and have not shown efficacy in limited clinical settings. Even with these mixed results, somatostatin analogs remain the only therapeutic alternative to patients with proliferative diabetic retinopathy who have failed to respond to panretinal photocoagulation.

UR - http://www.scopus.com/inward/record.url?scp=23744444437&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=23744444437&partnerID=8YFLogxK

U2 - 10.2165/00024677-200504040-00001

DO - 10.2165/00024677-200504040-00001

M3 - Article

VL - 4

SP - 199

EP - 203

JO - Treatments in Endocrinology

JF - Treatments in Endocrinology

SN - 1175-6349

IS - 4

ER -